PATENT CLAIM ANALYSIS

Application Number: 16025764
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["514", "470000"]

Abstract:
A method for decreasing the incidence rate and/or recurrent rate of cancer is provided. The method comprises administering to a subject in need an effective amount of butylidenephthalide (BP).

Claim (Index 4):
The method as claimed in  claim 2 , wherein the cancer stem cell (CSC) is at least one of oral cancer stem cells, nasopharyngeal cancer stem cells, esophageal cancer stem cells, myeloma stem cells, skin cancer stem cells, melanoma stem cells, thyroid cancer stem cells, lymphoma stem cells, leukemia stem cells, breast cancer stem cells, bladder cancer stem cells, ovarian cancer stem cells, cervical cancer stem cells, prostate cancer stem cells, gastric cancer stem cells, liver cancer stem cells, lung cancer stem cells, colon cancer stem cells, rectal cancer stem cells, pancreatic cancer stem cells, gall bladder cancer stem cells, renal cancer stem cells, thymic carcinoma stem cells and rhabdomyosarcoma stem cells.

Metadata:
- Claim Count in Document: 18.0
- Percentile: 95.0
- Lexical Diversity: 1.13793
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['13671274', '15774208', '12830993', '14982519', '14376923']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7586293746138995
- 35 USC 102 Novelty (BERT): 0.5163662193580877
- Combined Prediction Score: 0.7344030590883183
- Mean Citation Score: 228.790326
- Max Citation Score: 251.4584
- Similarity Product: 146.0720080842495

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test